FY2028 EPS Estimates for Viridian Therapeutics, Inc. Reduced by Analyst (NASDAQ:VRDN)

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2028 EPS estimates for shares of Viridian Therapeutics in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will earn $1.85 per share for the year, down from their prior forecast of $1.96. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.39) per share.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.28. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. During the same period in the prior year, the business posted ($1.61) EPS. The company's quarterly revenue was down 26.5% on a year-over-year basis.

VRDN has been the topic of a number of other reports. Oppenheimer dropped their target price on shares of Viridian Therapeutics from $36.00 to $31.00 and set an "outperform" rating on the stock in a report on Thursday. Wedbush upped their target price on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a report on Wednesday, February 28th. B. Riley cut shares of Viridian Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the company from $25.00 to $20.00 in a report on Thursday. LADENBURG THALM/SH SH cut shares of Viridian Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday. Finally, HC Wainwright lowered their price target on shares of Viridian Therapeutics from $37.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $34.60.

Viridian Therapeutics Trading Down 0.1 %

Shares of Viridian Therapeutics stock traded down $0.01 during trading hours on Friday, reaching $13.90. 858,045 shares of the company's stock were exchanged, compared to its average volume of 797,704. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $16.36 and a two-hundred day moving average of $17.62. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $28.35.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Viridian Therapeutics by 122.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company's stock worth $182,000 after purchasing an additional 4,610 shares during the period. Arizona State Retirement System acquired a new stake in shares of Viridian Therapeutics during the 4th quarter worth approximately $208,000. Principal Financial Group Inc. boosted its position in shares of Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company's stock worth $209,000 after acquiring an additional 1,058 shares in the last quarter. Raymond James & Associates boosted its position in shares of Viridian Therapeutics by 71.1% during the 3rd quarter. Raymond James & Associates now owns 15,164 shares of the company's stock worth $233,000 after acquiring an additional 6,303 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter worth approximately $264,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.